Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan
Abstract Background There is limited evidence that rituximab, a B cell depletion therapy, is an effective treatment for systemic lupus erythematosus (SLE). Data on the mechanisms of B cell depletion in SLE indicate that the combination of rituximab and belimumab may be more effective than rituximab...
Main Authors: | Patrick Muller, Kashfia Chowdhury, Caroline Gordon, Michael R. Ehrenstein, Caroline J. Doré |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-07-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-020-04391-2 |
Similar Items
-
Sequential therapy with rituximab and belimumab in patients with systemic lupus erythematosus
by: A. A. Mesnyankina, et al.
Published: (2020-11-01) -
Belimumab in systemic lupus erythematosus
by: Ankita Srivastava
Published: (2016-01-01) -
Belimumab in the treatment of Portuguese Systemic Lupus Erythematosus patients: a real-life multicenter study
by: Bruno Miguel Fernandes, et al.
Published: (2020-07-01) -
PROSPECTS FOR PHARMACOTHERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS
by: E. L. Nasonov, et al.
Published: (2014-06-01) -
Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
by: Sabih Ul Hassan, et al.
Published: (2020-08-01)